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Splicing of a Critical Exon of Human Survival Motor Neuron
Is Regulated by a Unique Silencer Element Located
in the Last Intron
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Humans have two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2. In
spinal muscular atrophy (SMA), SMN2 is not able to compensate for the loss of SMN1 due to exclusion of exon
7. Here we describe a novel inhibitory element located immediately downstream of the 5 splice site in intron
7. We call this element intronic splicing silencer N1 (ISS-N1). Deletion of ISS-N1 promoted exon 7 inclusion
in mRNAs derived from the SMN2 minigene. Underlining the dominant role of ISS-N1 in exon 7 skipping,
abrogation of a number of positive cis elements was tolerated when ISS-N1 was deleted. Confirming the silencer
function of ISS-N1, an antisense oligonucleotide against ISS-N1 restored exon 7 inclusion in mRNAs derived
from the SMN2 minigene or from endogenous SMN2. Consistently, this oligonucleotide increased the levels of
SMN protein in SMA patient-derived cells that carry only the SMN2 gene. Our findings underscore for the first
time the profound impact of an evolutionarily nonconserved intronic element on SMN2 exon 7 splicing.
Considering that oligonucleotides annealing to intronic sequences do not interfere with exon-junction complex
formation or mRNA transport and translation, ISS-N1 provides a very specific and efficient therapeutic target
for antisense oligonucleotide-mediated correction of SMN2 splicing in SMA.
Alternative splicing increases the coding potential of the
human genome by producing multiple proteins from a single
gene (2). It is also associated with a growing number of human
diseases (13, 15, 47). Regulation of alternative splicing is de-
pendent upon the relative concentrations of spliceosomal and
nonspliceosomal proteins, namely, serine-arginine-rich pro-
teins (SR proteins), SR-like proteins, and heterogeneous nu-
clear ribonucleoproteins (hnRNPs) (16, 35, 43). Some of these
proteins bind to pre-mRNA sequences called exonic splicing
enhancers (ESEs), intronic splicing enhancers, exonic splicing
silencers, and intronic splicing silencers (ISSs). Enhancers and
silencers promote or suppress splice site (ss) selection, respec-
tively. Over the last several years, methods have been devel-
oped to predict exonic cis elements (7, 12, 58). Analogous
methods to predict intronic cis elements do not exist. Local
RNA structure presents an additional level of splicing regula-
tion. Several studies have focused on RNA structures that
facilitate specific interactions during pre-mRNA splicing (3).
However, the role of critical RNA structures in pre-mRNA
splicing remains largely unpredictable.
Spinal muscular atrophy (SMA), the second most common
autosomal recessive disorder, is caused by the absence of the
Survival of Motor Neuron 1 (SMN1) gene (27). SMN1 encodes
a ubiquitously expressed 38-kDa SMN protein that is necessary
for snRNP assembly, an essential process for cell survival (57).
A nearly identical copy of the gene, SMN2, fails to compensate
for the loss of SMN1 because of exon 7 skipping, producing an
unstable truncated protein, SMN7 (30). SMN1 and SMN2
differ by a critical C-to-T substitution at position 6 of exon 7
(C6U in the transcript of SMN2) (31, 41). C6U does not
change the coding sequence but is sufficient to cause exon 7
skipping in SMN1. Two mutually exclusive models have been
proposed to explain the inhibitory effect of C6U. According to
one model, C6U abrogates an ESE associated with SF2/ASF
(5), whereas another model proposes that C6U creates an
exonic splicing silencer associated with hnRNP A1 (24). Based
on extensive mutations, we have demonstrated that C6U cre-
ates an extended inhibitory context (Exinct) at the 3 ss of exon
7 (Fig. 1) (50). The presence of Exinct was further supported
by in vivo selection of the entire exon 7 (51).
Exon 7 is known to have a weak 3 ss (29), probably due to
its suboptimal polypyrimidine tract. An improved polypyrimi-
dine tract promoted inclusion of exon 7 in SMN2 (32), sug-
gesting that the negative interactions at C6U and the positive
interactions at the polypyrimidine tract are mutually exclusive.
Several splicing factors have been implicated in modulation of
SMN exon 7 splicing. Most studied among them is the SR-like
protein Tra2-1 that binds to a purine-rich ESE in the middle
of exon 7 (18). Elevated expression of Tra2-1 (18) or its
associated proteins hnRNP G (19) and Srp30c (59) has been
shown to promote exon 7 inclusion in SMN2. A recent study in
which increased expression of the STAR (signal transduction
and activation of RNA) family of proteins promoted exclusion
of exon 7 suggests tissue-specific regulation (55). Proteins in-
teracting with intronic sequences may also affect regulation of
exon 7 splicing. Consistently, cis elements present in intron 6
and intron 7 have been shown to modulate exon 7 splicing (39,
40). These results highlight the complexity of pre-mRNA splic-
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ing in which exon 7 is defined by a network of interactions
involving several proteins.
Fifty-four-nucleotide-long exon 7 of human SMN genes con-
tains 65% AU residues. Hence, exon 7 fits the typical
definition of a cassette exon that generally contains a low
percentage of GC residues (9). To identify the position-
specific role of residues within the entire exon, we used a
systematic mutagenesis approach coupled with in vivo selec-
tion (51). This approach demonstrated for the first time the
feasibility of a functional assay in which the mutability of every
nucleotide within a given exon was determined (4). A highly
mutable position was considered inhibitory, whereas a con-
served position was considered stimulatory. Based on the mu-
tability plot of residues within exon 7, two unique inhibitory
regions, Exinct and 3-Cluster, both rich in AU residues,
were identified (Fig. 1) (51). According to in vivo selection
results, a non-wild-type guanosine residue (A54G substitution)
was preferred at the last position of exon 7, indicating that the
5 ss of exon 7 is weak. Confirming the inhibitory effect of the
last adenosine residue of exon 7, A54G obviated the require-
ment for a number of positive elements within exon 7 (51). The
mechanism by which A54G promotes exon 7 inclusion may
involve enhanced recruitment of U1 snRNP due to increased
base pairing between the U1 snRNA and the 5 ss of exon 7.
The strong stimulatory effect of A54G may also be associated
with the rearrangement in a predicted stem-loop structure that
is located at the 5 ss (52).
Intronic sequences located immediately upstream of the 3
ss or downstream of the 5 ss are functionally important in
splicing (38, 61). These sequences are highly diverse and could
be broadly categorized into GC-rich and AU-rich regions
that constitute distinct pentamer motifs (62). The intron 7
sequence downstream of the 5 ss is rich in A and U residues
but lacks characteristic pentamer motifs. Here we describe a
novel ISS element located downstream of the 5 ss of exon 7.
We call this element ISS-N1. Our findings highlight the role of
this unique intronic element in the regulation of human SMN
exon 7 splicing. We also report that ISS-N1 provides an effec-
tive therapeutic target for the antisense oligonucleotide-medi-
ated correction of SMN2 splicing in SMA.
MATERIALS AND METHODS
Minigenes. Minigene splicing cassettes pSMN1I6 and pSMN2I6 were con-
structed by deleting6 kb within intron 6 from pSMN1 and pSMN2, respectively
(50). For all of the experiments described in this report, SMN1 and SMN2 refer
to pSMN1I6 and pSMN2I6, respectively. Mutations were generated by PCR
by a strategy described earlier (50). Minigene splicing cassette Casp3 was con-
structed by amplifying genomic sequences starting from exon 5 to exon 7 of the
Caspase 3 gene with high-fidelity Pfx polymerase (Invitrogen), genomic DNA
(Clontech), and primers P53 (GTCCTCGAGTTTCTAAAGAAGATCAC
AGC) and P56 (GTCGCGGCCGCACCATCTTCTCACTTGGCAT). A PCR
fragment was subsequently digested with XhoI and NotI (NEB) and cloned into
vector pCI (Promega). Minigene splicing cassette Casp3Avr was generated by
inserting an AvrII restriction site (CCTAGG) into the Casp3 minigene down-
stream of an alternatively spliced exon 6 by high-fidelity PCR. Minigene splicing
cassette Casp3ISS-N1 was generated by inserting an ISS-N1 sequence (CCAG
CATTATGAAAG) at the AvrII restriction site in Casp3Avr. For the exact
locations of the AvrII and/or ISS-N1 sites, see Fig. 7C. Splicing cassettes
pTBEx9-V456F (CFTR exon 9 splicing), pTBEx12-50A (CFTR exon 12 splicing),
and pTBApo-ISE3m (apoA-II exon 3 splicing) are the same as in references 36,
45, and 46. Splicing cassettes CMV-Fas (wt) and CMV-Fas mutant (U-20C) (Fas
exon 6 splicing) are the same as in reference 22. Splicing cassette SI9/LI10 (Tau
exon 10 splicing) is the same as in reference 60.
Cell culture. Unless otherwise stated, all tissue culture media and supplements
were purchased from Invitrogen. Human cervical carcinoma (C33a) cells, human
embryonic kidney 293 (HEK-293) cells, and mouse motor neuron-like (NSC-34)
cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 g/ml streptomycin.
Human neuroblastoma (SK-N-SH) cells were maintained in a 1:1 mixture of
minimum essential medium (MEM) and Ham’s F12 medium supplemented with
10% FBS. Mouse neuroblastoma (Neuro-2a) cells were grown in MEM supple-
mented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1.0 mM
sodium pyruvate, and 10% FBS. Mouse embryonic teratocarcinoma (P19) cells
were maintained in -MEM supplemented with 10% FBS. All of the cells
mentioned above were obtained from the American Type Culture Collection.
NSC-34 cells were obtained from Neil Cashman (University of Toronto). Pri-
mary fibroblast cell lines from an SMA type I patient (GM03813) and a healthy
control (AG06814) were obtained from Coriell Cell Repositories. These cell
lines were maintained in MEM supplemented with 2 mM L-glutamine and 15%
FBS.
Antisense oligonucleotides. Antisense oligoribonucleotides were synthesized
by Dharmacon, Inc. The sequences of the oligonucleotides used are as follows:
Anti-N1, 5-mA*mU*mU*mC*mA*mC*mU*mU*mU*mC*mA*mU*mA*mA
*mU*mG*mC*mU*mG*mG-3; Anti-N1  10, 5-mC*mA*mA*mA*mA*mG
*mU*mA*mA*mG*mA*mU*mU*mC*mA*mC*mU*mU*mU*mC-3; An-
ti-N1  20, 5-mU*mA*mA*mA*mG*mU*mU*mU*mU*mA*mC*mA*mA
*mA*mA*mG*mU*mA*mA*mG-3; Anti-N1  30, 5-mC*mC*mA*mC*mA
*mA*mA*mC*mC*mA*mU*mA*mA*mA*mG*mU*mU*mU*mU*mA-3;
Scramble20, 5-mU*mC*mC*mU*mU*mU*mA*mA*mA*mG*mU*mA*mU
*mU*mG*mU*mG*mA*mC*mC; Anti-I7-25, 5-mA*mU*mU*mC*mA*mC
*mU*mU*mU*mC*mU*mA*mA*mA*mU*mU*mA*mA*mG*mG; Anti-ISS-
N1/15, 5-mC*mU*mU*mU*mC*mA*mU*mA*mA*mU*mG*mC*mU*mG
*mG-3. In these sequences, the letter m represents an O-methyl modification at
the second position of a sugar residue and an asterisk represents a phosphoro-
thioate modification of the backbone. Scramble20 and Anti-N1 have the same
sequence composition: three guanosines, four cytosines, five adenosines, and
eight uridines.
Transfections and in vivo splicing assays. All reagents were used according to
the manufacturer’s recommendations. Transient transfections of cells with plas-
FIG. 1. Model of cis elements that regulate splicing of exon 7 of human SMN. Uppercase letters represent exon 7 sequences. Lowercase letters
represent intronic sequences. The star represents position 6, where a C is replaced by a U (C6U) in SMN2 exon 7. The U1 snRNA binding site
that spans the first six nucleotides of intron 7 is shaded. Based on analysis of the entire exon 7 (51), three major cis elements (Exinct, Conserved
tract, and 3-Cluster) are shown. The putative binding sites of SF2/ASF (5) and hnRNP-A1 (24) fall within the inhibitory cis element Exinct. The
binding site of Tra2-1 (18) falls within the stimulatory cis element Conserved tract.
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mid DNA or antisense oligonucleotides were performed with Lipofectamine
2000 (Invitrogen). Cells were plated 24 h prior to transfection so that their
density on the day of transfection was 90%. For cotransfection experiments,
cells were transfected with the indicated amounts of plasmid DNA and an
oligonucleotide of interest. Oligonucleotide concentrations ranged from 25 to
500 nM. In a given experiment, the total amount of oligonucleotide was main-
tained constant by adding control oligonucleotide Scramble20. Unless indicated
otherwise, total RNA was isolated 24 h after transfection with Trizol reagent
(Invitrogen). To generate cDNA, reverse transcription was carried out with a
SuperScript II reaction kit (Invitrogen). An oligo(dT) primer was used for pCI-
based minigenes, while random hexamers and vector-specific 3 primer PT2
(5-AAGCTTGCATCGAATCAGTAG-3) were used for pTB vector-based
minigenes and Fas minigenes, respectively. Generally, 1.0 g of total RNA was
used per 20 l of reaction mixture. Minigene-specific spliced products were
subsequently amplified with Taq polymerase (Invitrogen) and the following
primer combinations: P1 (5-CGACTCACTATAGGCTAGCC-3) and P2 (5-
GCATGCAAGCTTCCTTTTTTCTTTCCCAACAC-3) for SMN minigenes
(50), alfa-23 (5-CAACTTCAAGCTCCTAAGCCACTGC-3) and BRA2 (5-T
AGGATCCGGTCACCAGGAAGTTGGTTAAATCA-3) for CFTR and
apoA-II minigenes (36, 45, 46), FP (5-GGTGTCCACTCCCAGTTCAA-3) and
RP (5 CCCTGGTTTATGATGGATGTTGCCTAATGAG) for Tau minigenes
(60), P1 and P55 (5-GTCGCGGCCGCATCCTTTGAATTTCGCCAAG-3)
for Casp3 minigenes, and PT1 (5-GTCGACGACACTTGCTCAAC-3) and
PT2 for Fas minigenes (22). Analysis and quantifications of spliced products
were performed with an FPL-5000 Image Reader and ImageGauge software
(Fuji Photo Film Inc.) (50). Results were confirmed by three independent ex-
periments.
Expression of endogenous genes. For GM03813 and AG06814 fibroblast trans-
fection, cells were plated at a density of 0.3  105 per well of a 24-well plate
1 day before transfection. On the next day, cells were transfected with an oligo-
nucleotide (from 5 to 200 nM). The total oligonucleotide amount was maintained
constant by adding the Scramble20 oligonucleotide. Unless indicated otherwise,
total RNA was isolated 24 h after transfection with Trizol reagent (Invitrogen).
Reverse transcription was carried out with an oligo(dT) primer and SuperScript
II (Invitrogen) as described above.
For PCR amplification of endogenous exons, the following primer combina-
tions were used: N-24 (5-CCAGATTCTCTTGATGATGCTGATGCTTTGG
G-3) and P2 (5-GCATGCAAGCTTCCTTTTTTCTTTCCCAACAC-3) for
SMN exon 7, Ex4Sense (5-CGGAATTCCAATGAAAATGAAAGCCAAGTT
TCAAC-3) and Ex6Anti (5-ATAGTTTAGCGGCCGCCATATAATAGCCA
GTATGATAG-3) for SMN exon 5, Ex1Sense (5-CGGAATTCCATGGCGA
TGAGCAGCGGCGGCAG-3) and Ex4Anti (5-ATAGTTTAGCGGCCGCC
TTTCCTGGTCCCAGTCTTGG-3-) for SMN exon 3, P53 and P56 for Caspase
3 exon 6, 5-Sur (GCATGGGTGCCCCGACGTTG) and 3-Sur (GCTCCGGC
CAGAGGCCTCAA) for Survivin exons 2B/3 (34), A1 (CATGAGCGACAGC
GG-CGAGCAGAA) and A3 (TTAATAGCGACGAGGTGAGTA) for Tra2
exons 2a/2b (8), 5Bcl-X (CATGGCAGCAGTAAAGCAAG) and 3Bcl-X (GC
ATTGTTCCCATAGAGTTCC) for Bcl-x exon 2 (37), and ex28F (GGAGTAC
ACCAAGTATCATGAG) and ex31R (CATTATGCTTGCAAAAACGAAC)
for NF1 exons 29/30 (48). Results were confirmed by three independent exper-
iments.
Antibodies and Western blot analysis. Transfections with antisense oligonu-
cleotides were done as described above. For each sample, the same number of
cells (9  105) was harvested 72 h after transfection and lysates were prepared
as described in reference 11. One-third of each lysate was used for one blot.
Lysates were electrophoresed on a 10% (wt/vol) sodium dodecyl sulfate-polyac-
rylamide gel electrophoresis gel, and the proteins were transferred onto polyvi-
nylidene fluoride membrane (Pall Life Sciences). The protein transfer and equal
loading were verified by SYPRO Ruby protein blot staining (Bio-Rad Labora-
tories). The membranes were blocked with 5% nonfat dried milk in TBST (20
mM Tris, 150 mM NaCl, 0.1% Tween 20) overnight at 4°C and subsequently
incubated with primary anti-SMN antibodies (BD Transduction Laboratories),
followed by washing and incubation with horseradish peroxidase-conjugated goat
anti-mouse immunoglobulin G (Jackson Immunoresearch). For a loading con-
trol, membranes were stripped with buffer containing 10 mM Tris, 75 mM NaCl,
1% sodium dodecyl sulfate, and 10 mM -mercaptoethanol (30 min at 60°C) and
reprobed for -tubulin. Monoclonal antibodies against -tubulin were from
Sigma. Immunoreactive proteins were visualized with SuperSignal West Dura
Extended Duration Substrate (Pierce). The membranes were scanned with a
LAS-1000 Image Reader (Fuji Photo Film Inc.). Results were confirmed by three
independent experiments.
RESULTS
Identification of a novel ISS. We have previously shown that
a weak 5 ss facilitates exon 7 exclusion in SMN2 (51). To
explore whether an intronic cis element contributes to the
weak 5 ss, we generated SMN2 minigene mutants with differ-
ent deletions at the 5 end of intron 7. We then determined the
in vivo splicing pattern of these mutants with highly transfect-
able cell line C33a (Fig. 2B). In all of the deletions, we retained
the first nine nucleotides of intron 7. These nucleotides are
conserved among mammals and harbor the canonical base-
pairing region for U1 snRNA, a component of U1 snRNP. We
first chose to make five-nucleotide-long deletions between po-
sitions 10 and 34 (mutants N110–14, N115–19, N120–24,
N125–29, and N130–34; Fig. 2B, lanes 4 to 8). Our analysis
revealed two inhibitory stretches, from position 10 to position
14 (CCAGC) and from position 20 to position 24 (GAAAG),
separated by a five-nucleotide sequence (AUUAU). Deletion
of GAAAG produced the strongest stimulatory effect (mutant
N120–24; Fig. 2B, lane 6), whereas deletion of CCAGC pro-
duced a moderate but noticeable stimulatory effect (mutant
N110–14; Fig. 2B, lane 4). Deletion of AUUAU produced no
stimulatory effect (mutant N115–19; Fig. 2B, lane 5), suggest-
ing that this deletion may strengthen an inhibitory element by
bringing the flanking sequences CCAGC and GAAAG to-
gether. Consistently, when AUUAU was deleted together with
either CCAGC or GAAAG, SMN2 exon 7 inclusion increased
(mutants N110–19 and N115–24; Fig. 2B, lanes 9 and 10,
respectively). In general, 10- or 15-nucleotide deletions that
did not include CCAGC or GAAAG produced no stimulatory
effect on exon 7 inclusion (mutants N125–34 and N125–39;
Fig. 2B, lanes 12 and 16, respectively).
The above results support the presence of a negative ele-
ment downstream of the U1 snRNA binding site in intron 7
between positions 10 and 24. We call it ISS-N1. To confirm
that the stimulatory effect of ISS-N1 deletion was not due to
the creation of an enhancer element, we made two additional
20- and 25-nucleotide-long deletions. Both deletions included
the complete ISS-N1 sequence (mutants N110–29 and
N110–34; Fig. 2A). Similar to ISS-N1 deletion (mutant
N110–24), they restored exon 7 inclusion in SMN2 to the
level of SMN1 (Fig. 2B, lanes 17 and 18). In all three mutants
(N110–24, N110–29, and N110–34), the nature of the se-
quences downstream of the U1 snRNA binding site was dif-
ferent, suggesting that exon 7 inclusion was not due to the gain
of a specific cis element but due to the loss of ISS-N1.
To determine whether ISS-N1-mediated downregulation of
exon 7 inclusion in SMN2 is tissue specific, we used five addi-
tional cell lines that included human SK-N-SH, HEK-293,
mouse Neuro-2a, mouse P19, and mouse NSC-34 cells. These
cell lines were transfected with the ISS-N1-deleted SMN2
minigene (mutant N110–24 in Fig. 2A). Hereafter, we refer
to mutant N110–24 as SMN2ISS-N1. Similar to the cervical
carcinoma cell line C33a (Fig. 2B), all cell types supported
exon 7 inclusion in SMN2ISS-N1 (Fig. 2C). Our results sug-
gest that ISS-N1-mediated suppression of SMN2 exon 7 inclu-
sion is not specific to a particular cell type.
ISS-N1 is absent in mouse Smn. In contrast to humans, mice
have a single Smn gene, which is equivalent to human SMN1.
Alignment of human and mouse introns 7 showed three sub-
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stitutions and three deletions in the ISS-N1 region of mouse
intron 7 (Fig. 3A). There are also four additional substitutions
in the 15-nucleotide-long stretch following ISS-N1. To test
whether differences between human and mouse intronic se-
quences affect splicing of exon 7, we exchanged the ISS-N1
region of our SMN2 minigene for the mouse sequence by
introducing three substitutions and three deletions (mutant
SMN2/MS8, Fig. 3A). This SMN2 mutant displayed full resto-
FIG. 2. Effects of intronic deletions downstream of the 5 ss of exon 7 of SMN2. (A) Intronic sequences of SMN2 deletion mutants. Nucleotide
numbering starts from the beginning of intron 7. Deletions are shown as dashed lines. The ISS-N1 site is shaded. Nucleotides involved in base
pairing with U1 snRNA are in bold and shaded. Numbers in mutants’ names represent the positions at which deletions were made. (B) In vivo
splicing pattern of SMN2 deletion mutants shown in panel A. The upper band corresponds to a fully spliced product that includes exon 7; the lower
band corresponds to an exon 7-skipped product. The percentage of exon 7 skipping was calculated from the total value of exon 7-included and exon
7-skipped products. Abbreviations E6, E7, and E8 stand for exon 6, exon 7, and exon 8, respectively. (C) In vivo splicing pattern of SMN2ISS-N1
(ISS-N1-deleted mutant) in different cell lines. Of note, SMN2ISS-N1 is the same construct as the N110–24 mutant in panel A. Cell lines used were
Neuro-2a (mouse brain neuroblastoma, lanes 1 to 3), NSC-34 (mouse motor neuron like, lanes 4 to 6), SK-N-SH (human neuroblastoma, lanes
7 to 9), P-19 (mouse embryonic teratocarcinoma, lanes 10 to 12), and HEK-293 (lanes 13 to 15). Spliced products are the same as those indicated
in panel B. NA, not applicable.
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ration of exon 7 inclusion (Fig. 3B, lane 11). To further dissect
the role of acquired mutations within ISS-N1, we tested the
splicing pattern of SMN2 mutants that incorporated different
combinations of deletions and substitutions corresponding to
mouse sequences. Consistent with the inhibitory role of ac-
quired mutations, a single A18U substitution in the middle of
ISS-N1 increased exon 7 inclusion in SMN2 from 19% to
34% (mutant SMN2/MS1, Fig. 3B, lane 4). When A18U was
combined with G20A, the exon 7 inclusion increased to 50%
(mutant SMN2/MS4, Fig. 3B, lane 7). A triple deletion from
position 11 to position 13 accounted for an increase of 28%
(from 19% to 47%) (mutant SMN2/MS6, Fig. 3B, lane 9).
When this triple deletion was combined with an adjacent C10U
substitution, exon 7 inclusion increased to 66% (mutant
SMN2/MS7, Fig. 3B, lane 10). As a control, we made substi-
tutions within sequences downstream of ISS-N1. Contrary to
the mutations within ISS-N1, the effects of these substitutions
were negligible (mutants SMN2/MS3 and SMN2/MS5, Fig. 3B,
lanes 6 and 8, respectively). These results are in full agreement
with the results of deletion mutations that defined the approx-
imate boundary of ISS-N1 in human intron 7 (Fig. 2A and B).
Antisense oligonucleotide validates the inhibitory role of
ISS-N1. To further confirm the presence of inhibitory element
ISS-N1, we designed a series of antisense oligonucleotides
(ribo-oligonucleotides) that were complementary to intronic
sequences downstream of the U1 snRNA binding site, includ-
ing the ISS-N1 region. Antisense oligonucleotide Anti-N1 fully
blocked ISS-N1 by annealing to a 20-nucleotide-long sequence
starting from position 10 of intron 7 (Fig. 4A). Antisense oli-
gonucleotide Anti-N110 partially targeted ISS-N1 by anneal-
ing to a sequence starting from position 20 of intron 7 (Fig.
4A). Anti-N120 and Anti-N130 annealed to sequences
downstream of ISS-N1 starting from positions 30 and 40, re-
spectively (Fig. 4A). To increase the intracellular stability of
oligonucleotides, all of them had a phosphorothioate backbone
and a 2-O-methyl modification in the sugar moiety. Antisense
oligonucleotides with similar modifications have been used to
correct aberrant splicing in vivo (10, 33). The effect of anti-
sense oligonucleotides on SMN2 splicing was determined by
cotransfection of C33a cells with 1.0 g of the SMN2 minigene
and 50 nM antisense oligonucleotides. Consistent with the
result obtained with deletion mutant N110–29 (Fig. 2B),
Anti-N1 restored exon 7 inclusion in SMN2 to the level of
SMN1 (Fig. 4B, lane 4). Complete restoration of SMN2 exon 7
inclusion was also observed at Anti-N1concentrations as low as
10 nM when the amount of the SMN2 minigene was reduced to
0.1 g (not shown). Three other antisense oligonucleotides
that annealed to the downstream sequences did not produce
any stimulatory effect (Fig. 4B, lanes 5 to 7). The results de-
FIG. 3. Evolutionary significance of ISS-N1. (A) Alignment of the first 42 nucleotides of human and mouse introns 7, including the ISS-N1
region. Numbering starts from the beginning of intron 7. ISS-N1 is shaded. Nucleotides involved in base pairing with U1 snRNA are in bold and
shaded. In the top two lines, positions homologous between the human and mouse sequences are shaded in black. In the bottom 10 lines, intronic
sequences of SMN2 mutants (SMN2/MS1 through SMN2/MS10) are shown with mouse nucleotides written in lowercase letters and shaded in
black. (B) In vivo splicing pattern of SMN2 mutants shown in panel A. Spliced products are the same as those indicated in Fig. 2B. NA, not
applicable.
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scribed were reproducible with two different batches of anti-
sense oligonucleotides synthesized at different times.
To confirm that Anti-N1 does not have a nonspecific effect
on alternative splicing of other exons, we performed the fol-
lowing experiment. C33a cells were transfected with different
minigenes in the presence and absence of Anti-N1, and in vivo
splicing patterns were determined. These minigenes were ran-
domly selected and represented a good mixture of exon-includ-
ing and exon-excluding cassettes (Fig. 4C). Among the mini-
genes that showed low skipping of exons were pTBEx9-V456F
(25% skipping of CFTR exon 9), pTBEx12-50A (20% skip-
ping of CFTR exon 12), pTBApo-ISE3m (15% skipping of
apoA-II exon 3), Casp3 (6% skipping of Caspase 3 exon 6),
and CMV-Fas (wt) (6% skipping of Fas exon 6). Among the
minigenes that showed mostly skipping of exons were SI9/LI10
(85% skipping of Tau exon 10) and CMV-Fas (U-20C)
(98% skipping of Fas exon 6). In the above experiments, we
used 50 nM Anti-N1 while the minigene-containing plasmid
concentration was decreased to 0.1 g. A high Anti-N1-to-
minigene ratio was deliberately chosen to detect the nonspe-
cific effect at the nonlimiting Anti-N1 concentration. Under-
scoring the specificity of Anti-N1 for SMN intron 7, we did not
notice an appreciable change in the splicing pattern of any of
the minigenes cotransfected with Anti-N1 (Fig. 4C).
The stimulatory effect of Anti-N1 is caused by base pairing
with the target sequence. To prove that the stimulatory effect
of Anti-N1 was solely due to blocking of ISS-N1, we performed
cotransfection experiments with SMN2 minigenes that had ran-
FIG. 4. Effects of antisense oligonucleotides on splicing of different minigenes. (A) Diagrammatic representation of intron 7 regions targeted
by antisense oligonucleotides Anti-N1, Anti-N110, Anti-N120, and Anti-N130. Numbering starts from the beginning of intron 7. The ISS-N1
region is shaded. Of the four oligonucleotides shown, only Anti-N1 fully sequestered ISS-N1. (B) In vivo splicing pattern of the SMN2 minigene
in the presence of antisense oligonucleotides. Spliced products are the same as those indicated in Fig. 2B. (C) In vivo splicing pattern of different
minigenes in the presence of Anti-N1. In every lane, the upper band represents the exon-included and the lower band represents the exon-excluded
products. In CFTR, apoA-II, Fas, and Casp3, the major bands represent the exon-included products. In Tau and Fas (U-20C), the major bands
represent the exon-excluded products. For detection of spliced products in lanes 1 to 6, 9, and 10, cells were harvested 40 h after transfection (for
other lanes, see Materials and Methods). The values on the left are sizes in base pairs. wt, wild type; NA, not applicable.
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dom mutations within ISS-N1 (Fig. 5A). Of note, from a large
library of ISS-N1 mutants, we chose only those in which sub-
stitutions did not affect SMN2 exon 7 inclusion but abrogated
base pairing between ISS-N1 and Anti-N1. Consequently,
upon cotransfection, Anti-N1 did not stimulate exon 7 inclu-
sion in any of these mutants (Fig. 5C). Remarkably, the stim-
ulatory effect of Anti-N1 completely disappeared even with a
mutant that had only a 2-bp mismatch with Anti-N1 (Fig. 5C,
lanes 7 and 8). Noticeably, Anti-N1 also reduced SMN1 exon 7
exclusion from 5% to 1% (Fig. 5C, compare lane 1 with
lane 2), suggesting that blocking of ISS-N1 has the potential to
upregulate SMN expression from both SMN1 and SMN2.
To further confirm that the observed antisense oligonucle-
otide-mediated stimulatory effect was due to base pairing be-
tween the antisense oligonucleotide and ISS-N1, we included a
mutant oligonucleotide in our cotransfection experiments
(Anti-I7-25, Fig. 5B and C). This oligonucleotide formed per-
fect base pairing with the ISS-N1 region of the SMN2/I7-25
minigene. We chose to target the SMN2/I7-25 construct delib-
erately since its ISS-N1 region contains five substitutions (a
33% change that includes a more-than-twofold increase in U
residues and a 33% decrease in G residues in 15-nucleotide-
long ISS-N1). Therefore, by using Anti-I7-25 we were able to
test the effect of base pairing in the mutant that retains inhib-
itory function despite a major change in the sequence compo-
sition. Remarkably, Anti-I7-25 produced an about sixfold in-
crease in exon 7 inclusion in SMN2/I7-25 (Fig. 5C, lane 15). At
the same time, Anti-I7-25 had no stimulatory effect on the
splicing pattern of the SMN1 or SMN2 minigene. Similarly,
Anti-I7-25 did not affect the splicing pattern of mutants SMN2/
I7-08 and SMN2/I7-09. The above results conclusively confirm
the inhibitory role of ISS-N1 and demonstrate that the anti-
sense oligonucleotides produce specific stimulatory effects on
exon 7 inclusion when ISS-N1 is blocked by base pairing.
Deletion of ISS-N1 rescues exon 7 inclusion in mutants with
abrogated positive cis elements. To assess the relative impact
of ISS-N1 on exon 7 splicing, we generated SMN1 mutants in
which ISS-N1 deletion was combined with abrogation of one of
the stimulatory cis elements. In particular, we tested the impact
of ISS-N1 deletion on inhibitory substitutions within four pos-
itive cis elements, i.e., intronic element 2 (39, 40), Tra2-ESE
(18), Conserved tract (51), and a critical guanosine residue at
the first position of exon 7 (50, 51). A diagrammatic represen-
tation of the relative positioning of these elements is shown in
Fig. 6A. Demonstrating the cross-exon effect, deletion of
ISS-N1 fully restored exon 7 inclusion in SMN1 harboring a
guanosine-to-uridine substitution at the first position of exon 7
(mutant SMN1ISS-N1/1U, Fig. 6B, lane 9). Similarly, dele-
tion of ISS-N1 promoted exon 7 inclusion in SMN1 mutants
with abrogated element 2 (mutant SMN1ISS-N1/Abr-E2,
Fig. 6B, lane 8) and abrogated Tra2-ESE (mutant SMN1ISS-
N1/Abr-Tra2, Fig. 6B, lane 10). Although less prominent, the
stimulatory effect of ISS-N1 deletion was clearly detectable in
an SMN1 mutant with an abrogated Conserved tract (mutant
SMN1ISS-N1/Abr-CT, Fig. 6B, lane 11). These results dem-
onstrate for the first time that a single intronic element has
such a strong impact on exon 7 splicing in SMN genes.
ISS-N1 shows portability within SMN2 intron 7, as well as in
a heterologous system. To demonstrate the portability of
ISS-N1 within intron 7, we generated four mutants in which
FIG. 5. Effect of base pairing between Anti-N1 and ISS-N1 on the efficiency of SMN2 exon 7 inclusion. (A) Intron 7 sequences of SMN2 and
mutants with substitutions in the ISS-N1 region. Numbering starts from the beginning of intron 7. The ISS-N1 region is shaded in gray. Nucleotides
involved in base pairing with U1 snRNA are in bold and shaded. Note that intronic mutations (shaded in black) abrogate base pairing between
Anti-N1 and ISS-N1. (B) Sequences of Anti-N1 and Anti-I7-25 oligonucleotides. Differences are shaded in black. Note that Anti-I7-25 restores
base pairing with the ISS-N1 region in mutant SMN2/I7-25. (C) In vivo splicing pattern of mutants shown in panel A. Plasmid DNA (0.1 g) was
transfected alone or cotransfected with 50 nM Anti-N1 or Anti-I7-25 oligonucleotide. Spliced products are the same as those indicated in Fig. 2B.
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ISS-N1 was moved away from the 5 ss of SMN2 exon 7 (Fig.
7A, top). We then tested the splicing pattern of these mutants.
While moving ISS-N1 five nucleotides away from its original
position fully retained the inhibitory impact of ISS-N1 (Fig. 7B,
lane 3), there was a little decrease in the inhibitory effect (from
89% to 72%) when ISS-N1 was moved another five nucle-
otides (Fig. 7B, lane 4). Moving of ISS-N1 20 nucleotides away
from its original position produced a dramatic effect in which
exon 7 exclusion decreased from 89% to 18% (Fig. 7B,
lane 5). Further moving of ISS-N1 by another 15 nucleotides
completely eliminated the inhibitory impact of ISS-N1 and
restored exon 7 inclusion in SMN2 to the level of SMN1 (Fig.
7B, lane 6). These results demonstrate the limited portability
of ISS-N1 in which the inhibitory effect of ISS-N1 seems to be
tied to its close proximity to the 5 ss.
The observation that moving ISS-N1 five nucleotides away
from its original position fully retained the inhibitory impact of
ISS-N1 (mutant ISS-N1-M5 in Fig. 7A) suggests that the na-
ture of the five-nucleotide-long sequence UGAAU that imme-
diately precedes ISS-N1 was unable to break the inhibitory
context responsible for the ISS-N1-mediated exclusion of exon
7. To determine whether the ISS-N1-associated inhibitory im-
pact is context specific, we examined the effects of five-nucle-
otide-long insertions immediately preceding ISS-N1 (Fig. 7A,
bottom). Insertion of five guanosine residues that created an
eight-nucleotide-long GC-rich stretch upstream of ISS-N1 did
not change exon 7 splicing in SMN2 (Fig. 7B, lane 12). Simi-
larly, insertion of five adenosines upstream of ISS-N1 had a
negligible effect on the splicing pattern of SMN2 (Fig. 7B, lane
9). Insertion of five C residues created a stretch of seven
cytosines and partially improved exon 7 inclusion in SMN2
(Fig. 7B, lane 11). However, insertion of five uridines allevi-
ated the inhibitory effect of ISS-N1 and substantially increased
SMN2 exon 7 inclusion (Fig. 7B, lane 10). These results suggest
that the inhibitory impact of the ISS-N1 element is not only
dependent upon the proximity of ISS-N1 to the 5 ss but is also
intimately connected to the nature of sequences immediately
upstream of ISS-N1. As controls, we tested the impact of
identical insertion mutations in SMN1. Underscoring that
these insertions have no independent inhibitory effect, none of
these mutations affected SMN1 exon 7 splicing (Fig. 7B, lanes
13 to 17).
Having demonstrated the limited portability of ISS-N1
within intron 7 of SMN2, we decided to check the portability of
ISS-N1 in a heterologous context, with a Casp3 minigene that
contains the Caspase 3 genomic sequence from exon 5 through
exon 7. This minigene recapitulates the partial skipping of
endogenous Caspase 3 exon 6 reported by Huang et al. (21).
Insertion of an AvrII restriction site downstream of exon 6 did
not change the splicing pattern of exon 6 (compare lane 1 in
Fig. 7D with lane 13 in Fig. 4C) but allowed us to insert ISS-N1
for testing the portability of this element in a heterologous
context. As shown in Fig. 7C, we inserted the ISS-N1 sequence
nine nucleotides away from the 5 ss of exon 6 (mutant
Casp3ISS-N1, Fig. 7C). We deliberately chose this position
because ISS-N1 is located at the identical position within in-
tron 7 of SMN genes (Fig. 2A). Interestingly, ISS-N1 insertion
caused an about sixfold increase in skipping of Casp3 exon 6
(Fig. 7D, compare lane 1 with lane 3). Blocking of ISS-N1 by
a 15-nucleotide-long antisense oligonucleotide (Anti-ISS-N1/
15) fully restored the inclusion of Casp3 exon 6 (Fig. 7D,
compare lane 4 with lane 3). We used the SMN2 minigene as
the positive control for testing the effect of Anti-ISS-N1/15. As
expected, Anti-ISS-N1/15 fully restored exon 7 inclusion in
transcripts derived from the SMN2 minigene. The above re-
sults confirm that ISS-N1 is a portable inhibitory element even
in a heterologous context. Remarkably, ISS-N1 was able to
exert its inhibitory impact despite the presence of G residues at
the first and last positions of exon 6 in Casp3 (Fig. 7C). We
have previously shown that the presence of a G residue at the
FIG. 6. Relative significance of exon 7 cis elements vis-a`-vis ISS-N1. (A) Diagrammatic representation of several cis elements involved in
regulation of exon 7 splicing (not to scale). 1G, Tra2-1 (Tra2-ESE), CT (Conserved tract), and element 2 represent positive elements (). ISS-N1
is a negative element (	). (B) In vivo splicing pattern of SMN1 mutants in which deletion of ISS-N1 (ISS-N1) was combined with abrogation of
a given positive cis element. Spliced products are the same as those indicated in Fig. 2B. Abr-E2 represents abrogation of element 2 by a triple
substitution G69C/U70A/U71A in intron 7 (40), Abr-Tra2 represents abrogation of Tra2-ESE by a 25U26U mutation in exon 7 (18), 1U mutation
represents abrogation of a cis element at the first position (51), and Abr-CT represents abrogation of Conserved tract by a 36U37U mutation in
exon 7 (51).
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FIG. 7. Portability of ISS-N1. (A, top) Location of ISS-N1 within SMN2 intron 7 with respect to the 5 ss. ISS-N1 was inserted at different
locations within intron 7 of SMN2ISS-N1. (A, bottom) Intronic sequences of SMN2 mutants with five-nucleotide-long insertions immediately
upstream of ISS-N1. Nucleotide positions and types of insertions are indicated. Numbering starts from the beginning of intron 7. ISS-N1 is shaded.
Nucleotides involved in base pairing with U1 snRNA are in bold and shaded. (B) In vivo splicing pattern of mutants shown in panel A. Spliced
products are the same as those indicated in Fig. 2B. (C) Insertion of ISS-N1 in a heterologous context. For insertion of ISS-N1, an AvrII restriction
site was first inserted downstream of exon 6 of the Casp3 minigene. (D) In vivo splicing pattern of mutants shown in panel C. The splicing pattern
was determined in the absence and presence of an antisense oligonucleotide (Anti-ISS-N1/15) that fully sequesters ISS-N1. In the absence of
Anti-ISS-N1/15, the Casp3ISS-N1 mutant increases exclusion of Casp3 exon 6 (compare lane 3 with lane 4). NA, not applicable.
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last position of exon 7 in SMN2 renders exon 7 exclusion
undetectable even in a sensitive radioactive assay (51).
Anti-N1 corrects the aberrant splicing of endogenous SMN2
and increases SMN protein in SMA cells. Since the studies
described above were performed with SMN minigenes, we de-
cided to validate the inhibitory activity of ISS-N1 in the context
of endogenous SMN2. The SMA type I fibroblast line
GM03813 carries the entire SMN2 but no SMN1. Accordingly,
these cells produce high levels of exon 7-excluded products
(Fig. 8A, lane 2). As expected, transfection of GM03813 cells
(SMA cells) with increasing concentrations of Anti-N1 yielded
increased exon 7 inclusion (not shown). The minimum concen-
tration at which the level of exon 7 inclusion in SMA cells
increased to the level observed in normal fibroblasts was 5 nM.
Consequently, we transfected SMA cells with 5 nM antisense
oligonucleotides (Anti-N1, Anti-N1  10, Anti-N1  20, and
Anti-N1  30). The annealing positions of the above oligonu-
cleotides are the same as those shown in Fig. 4A. Only Anti-N1
restored exon 7 inclusion in SMA cells comparable to that of
normal fibroblasts (Fig. 8A). Three other oligonucleotides pro-
duced no appreciable stimulatory effects (Fig. 8A). The exper-
iments were reproducible with two batches of oligonucleotides.
These results validate the inhibitory role of ISS-N1 in the
context of an endogenous SMN2 transcript.
FIG. 8. Effect of Anti-N1 on the splicing of endogenous genes. (A) Splicing of endogenous SMN2 after SMA fibroblasts (GM03813) were
transfected with 5 nM oligonucleotides. Total RNA was collected 25 h after transfection. (B) Specificity of the effect of Aniti-N1 on the splicing
pattern of other exons in SMA fibroblasts (GM03813). The sizes of the expected spliced products are indicated on the left. The same RNA as that
used in panel A (lanes 2 and 3) was used for analysis. The 662-bp bands in lanes 1 and 2 represent the SMN exon 3-included product, and the 387-bp
bands in lanes 3 and 4 represent the SMN exon 5-included product. The 440-bp bands in lanes 5 and 6 represent transcripts that exclude exon 2b
but include exon 3 of Survivin (34). The 830-bp bands in lanes 7 and 8 represent transcripts that include exons 29 and 30 of NF1 (48). The 686-bp
bands in lanes 9 and 10 represent transcripts that produce a Tra2-1 spliced variant of Tra2 (8). The 474-bp bands in lanes 11 and 12 represent
the Caspase 3 exon 6-included product (21). The 300-bp bands in lanes 13 and 14 represent a Bcl-xL spliced variant of Bcl-x (37). (C) Effect of
Aniti-N1 on the level of SMN protein. Western blotting was performed to detect SMN in SMA fibroblasts (GM03813) transfected with 5 nM (lane
1) and 15 nM (lane 3) Anti-N1. GM03813 cells transfected with control oligonucleotide Scramble20 (lanes 2 and 4) and mock-transfected
GM03813 cells (lane 5) or AG06814 cells (normal fibroblasts) (lane 6) were used as controls. For detection of SMN, cells were harvested 72 h after
transfection. We used -tubulin as a loading control. The values on the left are sizes in base pairs.
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To confirm that Anti-N1 does not cause aberrant splicing of
other exons in patient cells, we performed the following exper-
iment. RNA preparations from untreated fibroblasts and fibro-
blasts treated with 5 nM Anti-N1 (Fig. 8A, lanes 2 and 3) were
used to determine the splicing pattern of a limited number of
the randomly selected endogenous genes that are known to
generate alternatively spliced products (8, 21, 34, 37, 48). We
did not find a detectable change in the splicing pattern of any
of the examined genes, including Tra2, which produces
Tra2-1 (compare the 868-bp bands in lanes 9 and 10 in Fig.
8B) (8). Tra2-1 plays a stimulatory role in SMN2 exon 7
inclusion but is downregulated in SMA patient cells (17). Also,
the splicing pattern of SMN exons 3 and 5 remained unaffected
in patient cells treated with Anti-N1. These exons have been
shown to undergo alternative splicing (20). Despite the small
sample size, our results do not support a global adverse effect
of Anti-N1 on the alternative splicing of other genes.
To demonstrate that Anti-N1-mediated blocking of ISS-N1
leads to increased levels of SMN protein, we treated SMA cells
with 5 or 15 nM Anti-N1. These concentrations fall within the
lower range of Anti-N1 concentrations that corrected SMN2
splicing in patient cells. Both concentrations caused a signifi-
cant increase in the SMN protein level (Fig. 8C). This is the
first report of a study in which an antisense oligonucleotide-
assisted increase in the level of SMN protein in patient cells
was detected by Western blotting. This may have been possible
due to a more-than-fivefold increase in exon 7 inclusion from
the endogenous SMN2 minigene (Fig. 8A). The level of SMN
protein remained elevated for 5 days after transfection. To
confirm the specificity of Anti-N1-induced stimulation, we
used a scrambled oligonucleotide as a negative control. As
shown in Fig. 8C (lanes 2 and 4), this oligonucleotide did not
produce any detectable increase in the levels of SMN protein.
DISCUSSION
Alternative pre-mRNA splicing is a complex event in which
cis elements located in both exonic and intronic sequences play
an important role. Compared to exonic cis elements, the role
of intronic cis elements in the modulation of alternative splic-
ing is poorly understood (54). Further, there are no algorithms
to accurately predict intronic cis elements. The task of identi-
fying intronic cis elements is also complicated by the large size
of introns. Here we describe a novel intronic cis element,
ISS-N1 (CCAGCAUUAUGAAAG), which is located in the
nonconserved portion of the final intron (intron 7) of human
SMN. This element was found to be an important component
of a regulatory network that modulates alternative splicing of
SMN exon 7, which is linked to the pathogenesis of SMA.
We began this study as a follow-up to one of the important
findings of our in vivo selection: a weak 5 ss is the dominant
cause of exon 7 exclusion in SMN2 (51). Consistently, we
demonstrated that exonic sequences near the 5 ss of exon 7
form an inhibitory element called 3-Cluster. Interestingly, 3-
Cluster was found to overlap sequences that are not conserved
among mammals, suggesting an evolutionary constraint in
which a novel regulatory network evolved just before the du-
plication of SMN. Such an arrangement may even have favored
SMN duplication as SMN expression was already under the
tight control of inhibitory cis elements that rendered the 5 ss
of exon 7 poorly accessible. We reasoned that the noncon-
served intronic sequences might have played a key role in
creating a poorly accessible 5 ss. Thus, we analyzed a series of
deletion mutations within adjacent intron 7. This led to the
identification of ISS-N1, an inhibitory cis element located im-
mediately downstream of the 5 ss in intron 7 of human SMN
genes (Fig. 2).
The observation that substitutions in the nonconserved por-
tions of intron 7 restore exon 7 inclusion in SMN2 reveals the
significance of noncoding sequences that acquired an addi-
tional function during evolution to downregulate SMN expres-
sion (Fig. 3). Our results support a hypothesis that human-
specific alternative splicing of exons may be linked to the
evolutionarily divergent intronic sequences. Interestingly, the
sequence between positions 7 and 30 of intron 7 was found to
be more conserved (67%) than expected (55%) based on
the statistical prevalence of conserved residues between the
human and mouse intronic sequences downstream of a consti-
tutively spliced exon (54). This underscores that the type of
mutations, not their number, played a significant role in cre-
ating novel cis elements during evolution. It is not known if the
mouse sequence that corresponds to ISS-N1 contains an en-
hancer element that is recognized by a splicing factor. Inter-
estingly, this region in the mouse contains a UUUAA motif,
which has been found to be a winning pentamer within low
GC content intronic sequences downstream of the 5 ss (62).
Winning pentamers supposedly regulate splicing by an as yet
unknown mechanism. Since an ISS-N1-deleted mutant pro-
moted exon 7 inclusion in all cell lines, including mouse cells,
we conclude that tissue-specific factors are not involved in
ISS-N1-mediated regulation of alternative splicing of exon 7
(Fig. 2C). These results also demonstrate how the relatively
conserved pre-mRNA processing machinery uses noncon-
served intronic cis elements to achieve human-specific regula-
tion.
We used an antisense oligonucleotide-based approach to
conclusively demonstrate the inhibitory nature of ISS-N1 (Fig.
4). In this approach, the ISS-N1 sequence was blocked by
antisense oligonucleotide Anti-N1. As expected, Anti-N1 fully
restored exon 7 inclusion in the SMN2 minigene. The positive
effect of Anti-N1 was very specific to SMN exon 7, as no
off-target effect on alternative splicing was observed in a com-
prehensive test that used eight other minigenes (Fig. 4C). In
addition, we found that the Anti-N1-mediated stimulatory ef-
fect is exclusively dependent upon base pairing with the target
(Fig. 5). Consistently, a mutant oligonucleotide (Anti-I7-25)
that restored base pairing with a mutated form of ISS-N1
(SMN2/I7-25) also promoted exon 7 inclusion in SMN2. Since
both deletion of ISS-N1 and substitutions within ISS-N1 pro-
moted exon 7 inclusion in SMN2 (Fig. 2 and 3), we conclude
that antisense oligonucleotide-mediated stimulation of exon 7
inclusion is due solely to blocking of ISS-N1 and not to a
nonspecific effect of an RNA-RNA duplex which is formed by
annealing of Anti-N1 to ISS-N1. The fact that antisense oligo-
nucleotides that annealed to sequences downstream of ISS-N1
produced no changes in the splicing pattern (Fig. 4B) also rules
out the possibility of any stimulatory effect merely due to a
double-stranded RNA.
The observation that deletion of ISS-N1 compensates for a
number of abrogated stimulatory cis elements suggests that
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ISS-N1 plays a critical role in alternative splicing of exon 7.
ISS-N1 is strategically placed in the vicinity of the 5 ss, which
is poorly defined for several reasons, including poor base pair-
ing with U1 snRNA, a component of U1 snRNP. Consistently,
we have previously demonstrated that a single nucleotide sub-
stitution (A54G) that increased base pairing between the 5 ss
and U1 snRNA from six to eight nucleotides promoted exon 7
inclusion in SMN2 (51). Interestingly, we found a striking sim-
ilarity between the stimulatory effects produced by the A54G
mutation and the ISS-N1 deletion. In both cases, exon 7 inclu-
sion was restored despite the abrogation of a number of pos-
itive cis elements. These results support a very tight control by
which the 5 ss of SMN exon 7 is recognized. One of the
possible mechanisms by which ISS-N1 exerts its inhibitory im-
pact may involve rendering the 5 ss inaccessible for the re-
cruitment of U1 snRNP. Consistently, moving ISS-N1 away
from the 5 ss promoted exon 7 inclusion in SMN2.
The splicing pattern of SMN2 mutants in which ISS-N1 was
moved 5 or 10 nucleotides away from its original location
demonstrated the portability of ISS-N1. These mutations also
delineated the 5 and 3 boundaries of ISS-N1 and confirmed
that intronic sequences immediately upstream and down-
stream of ISS-N1 are not associated with the inhibitory role of
ISS-N1. However, the portability of ISS-N1 was not absolute as
moving ISS-N1 20 or 35 nucleotides away from its original
location restored exon 7 inclusion in SMN2. The limitation of
ISS-N1 portability was also revealed by the insertion mutation
in which addition of five U residues between the 5 ss and
ISS-N1 substantially increased exon 7 inclusion in SMN2. This
underscores the specific role of an inhibitory context in which
ISS-N1 must cooperate with other negative elements to pro-
duce the net effect of exon 7 exclusion during pre-mRNA
splicing of SMN2. Insertion of U residues may have disrupted
this context by creating an enhancer element and/or by pro-
viding better accessibility to the 5 ss through a favorable RNA
structure. Consistently, we observed that ISS-N1 was less in-
hibitory in a heterologous context when it was inserted nine
nucleotides away from the 5 ss of exon 6 of the Casp3 mini-
gene. However, the impact of ISS-N1 on Casp3 exon 6 was still
greater than that on exon 7 of SMN1, which differs from SMN2
by a critical C6U mutation. This observation highlights how the
impact of an intronic cis element is altered by exonic mutations
that are located more than 60 nucleotides away (C6U in SMN2
and mutant SMN1/1U in Fig. 6).
Use of antisense oligonucleotide Anti-N1 confirmed the
presence of ISS-N1 in the context of the endogenous gene,
which is transcribed from a different promoter than the mini-
gene. Further, the endogenous transcript is more than 25-fold
larger than the transcript derived from the SMN2 minigene
used in our study. There are several ways in which transcription
and the transcript size could affect alternative splicing (1, 26).
The fact that blocking of ISS-N1 by low concentrations of
Anti-N1 restored exon 7 inclusion in mRNA derived from
endogenous SMN2 demonstrated the feasibility of an intron-
interacting oligonucleotide to fully overcome the inhibitory
effect of an exonic mutation responsible for producing a trun-
cated protein in patient cells. Such a strong antisense effect is
possible only when the antisense target is easily accessible. The
strong stimulatory effect of Anti-N1 may also suggest that
blocking of ISS-N1 lessens the dependency on exon 7 inclu-
sion-inducing factor Tra2-1, which is downregulated in SMA
(17).
The majority of SMA cases are caused by the deletion of
both SMN1 alleles (28). Fortunately, most patients retain a
copy of SMN2 that could be used to produce the full-length
SMN protein. For antisense oligonucleotide-based therapy of
SMA, an intronic site is likely to present a better target be-
cause an intron-annealed oligonucleotide will not interfere
with downstream mRNA metabolism, including exon-junction
complex formation, transport, and translation (44). Consis-
tently, we observed increased levels of SMN protein in SMA
cells treated with Anti-N1 at a concentration as low as 5 nM. In
contrast, a prior study that used a bifunctional oligonucleotide
which annealed to exon 7 and required the presence of splicing
factor SF2/ASF produced a stimulatory effect on SMN2 exon 7
inclusion at a concentration of 100 nM (53). Effects on the
protein level for other antisense oligonucleotides that pro-
moted exon 7 inclusion in SMN2 minigenes have not been
reported (6, 29, 39).
Antisense oligonucleotide-based therapy might have utility
in a number of human diseases associated with aberrant splic-
ing (10, 13, 25, 49). A recent study demonstrated antisense
oligonucleotide-mediated correction of aberrant splicing re-
sulting in the restoration of expression of dystrophin in body-
wide skeletal muscles of the mouse model of Duchenne mus-
cular dystrophy (33). Mouse models of SMA are available (20,
42). However, for therapeutic applications of antisense oligo-
nucleotides in neuromuscular diseases such as SMA, addi-
tional modifications may be required for oligonucleotides to
cross the blood-brain barrier. Recent advancements in nucleic
acid technology and delivery strategies have broadened the
scope of antisense oligonucleotide usage for neuronal disor-
ders (14, 23, 56). Currently, SMA has no therapy. Our discov-
ery of ISS-N1 provides a very specific and accessible intronic
target to develop an effective antisense oligonucleotide-based
therapy for SMA.
In summary, we have discovered a novel splicing-inhibitory
cis element, ISS-N1, which is located in the final intron of
human SMN genes. Deletion of ISS-N1 fully corrected SMN2
splicing and compensated for the loss of a number of positive
splicing elements within SMN1. This is the first report demon-
strating the profound impact of an intronic cis element on
alternative splicing of human SMN genes. Blocking of ISS-N1
by an antisense oligonucleotide restored exon 7 inclusion in
SMN2 and elevated the levels of SMN protein in SMA patient
cells. These findings bring new insights into our understanding
of human SMN splicing and provide a unique target for cor-
recting the defective gene associated with a devastating disease
of infants and children.
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